NIH-defined graft-versus-host disease and evidence for a potent graft-versus-leukemia effect in patients with acute lymphoblastic leukemia

Annals of Oncology

Volumn 24, Issue 5, 2013, Pages 1363-1370

  Terwey, T H ^a   Le Duc, T M ^a   Hemmati, P G ^a   le Coutre, P ^a   Nagy, M ^a   Martus, P ^b   Dorken B ^a   Arnold, R ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Acute lymphoblastic leukemia; GVHD; GVL; NIH consensus criteria

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; ETOPOSIDE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; THYMOCYTE ANTIBODY; TREOSULFAN;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CANCER MORTALITY; CHRONIC GRAFT VERSUS HOST DISEASE; DONOR LYMPHOCYTE INFUSION; FEMALE; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LEUKEMIA RELAPSE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS;

ADOLESCENT; ADULT; DISEASE-FREE SURVIVAL; FEMALE; GRAFT VS HOST DISEASE; GRAFT VS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TRANSPLANTS; YOUNG ADULT;

EID: 84877107723     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds615     Document Type: Article

References (47)

1. Filipovich AH, Weisdorf D, Pavletic S et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graftversus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11: 945-956.
2. Sullivan KM. Graft-versus-host disease. In Thomas ED, Blume KG, Forman SJ (eds), Hematopoietic Cell Transplantation. Malden, MA: Blackwell Sciences, 1999; 515-536.
3. Socie G. The NIH consensus criteria for chronic graft-versus-host disease: far more than just another classification. Leukemia 2009; 23: 1-2.
4. Pidala J, Kim J, Anasetti C et al. The global severity of chronic graft-versus-host disease, determined by National Institutes of Health consensus criteria, is associated with overall survival and non-relapse mortality. Haematologica 2011; 96: 1678-1684.
5. Sato T, Ichinohe T, Kanda J et al. Clinical significance of subcategory and severity of chronic graft-versus-host disease evaluated by National Institutes of Health consensus criteria. Int J Hematol 2011; 93: 532-541.
6. Lee JW, Lee DH, Jang PS et al. Prognostic implications of the NIH consensus criteria in children with chronic graft-versus-host disease. Yonsei Med J 2011; 52: 779-786.
7. Kuzmina Z, Eder S, Bohm A et al. Significantly worse survival of patients with NIH-defined chronic graft-versus-host disease and thrombocytopenia or progressive onset type: results of a prospective study. Leukemia 2012; 26: 746-756.
8. Arai S, Jagasia M, Storer B et al. Global and organ-specific chronic graft-versushost disease severity according to the 2005 NIH Consensus Criteria. Blood 2011; 118: 4242-4249.
9. Kim DY, Lee JH, Kim SH et al. Reevaluation of the National Institutes of Health criteria for classification and scoring of chronic GVHD. Bone Marrow Transplant 2010; 45: 1174-1180.
10. Cho BS, Min CK, Eom KS et al. Feasibility of NIH consensus criteria for chronic graft-versus-host disease. Leukemia 2009; 23: 78-84.
11. Arora M, Nagaraj S, Witte J et al. New classification of chronic GVHD: added clarity from the consensus diagnoses. Bone Marrow Transplant 2009; 43: 149-153.
12. Vigorito AC, Campregher PV, Storer BE et al. Evaluation of NIH consensus criteria for classification of late acute and chronic GVHD. Blood 2009; 114: 702-708.
13. Jagasia MH, Savani BN, Stricklin G et al. Classic and overlap chronic graftversus-host disease (cGVHD) is associated with superior outcome after extracorporeal photopheresis (ECP). Biol Blood Marrow Transplant 2009; 15: 1288-1295.
14. Jagasia M, Giglia J, Chinratanalab W et al. Incidence and outcome of chronic graft-versus-host disease using National Institutes of Health consensus criteria. Biol Blood Marrow Transplant 2007; 13: 1207-1215.
15. Thepot S, Zhou J, Perrot A et al. The graft-versus-leukemia effect is mainly restricted to NIH-defined chronic graft-versus-host disease after reduced intensity conditioning before allogeneic stem cell transplantation. Leukemia 2010; 24: 1852-1858.
16. Terwey TH, Vega-Ruiz A, Hemmati PG et al. NIH-defined graft-versus-host disease after reduced intensity or myeloablative conditioning in patients with acute myeloid leukemia. Leukemia 2012; 26: 536-542.
17. Kolb HJ. Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood 2008; 112: 4371-4383.
18. Loren AW, Porter DL. Donor leukocyte infusions for the treatment of relapsed acute leukemia after allogeneic stem cell transplantation. Bone Marrow Transplant 2008; 41: 483-493.
19. Kolb HJ, Schattenberg A, Goldman JM et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995; 86: 2041-2050.
20. Collins RH, Jr, Goldstein S, Giralt S et al. Donor leukocyte infusions in acute lymphocytic leukemia. Bone Marrow Transplant 2000; 26: 511-516.
21. Choi SJ, Lee JH, Lee JH et al. Treatment of relapsed acute lymphoblastic leukemia after allogeneic bone marrow transplantation with chemotherapy followed by G-CSF-primed donor leukocyte infusion: a prospective study. Bone Marrow Transplant 2005; 36: 163-169.
22. Cardoso AA, Schultze JL, Boussiotis VA et al. Pre-B acute lymphoblastic leukemia cells may induce T-cell anergy to alloantigen. Blood 1996; 88: 41-48.
23. Hirano N, Takahashi T, Takahashi T et al. Expression of costimulatory molecules in human leukemias. Leukemia 1996; 10: 1168-1176.
24. Ruggeri L, Capanni M, Urbani E et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002; 295: 2097-2100.
25. Passweg JR, Tiberghien P, Cahn JY et al. Graft-versus-leukemia effects in T lineage and B lineage acute lymphoblastic leukemia. Bone Marrow Transplant 1998; 21: 153-158.
26. Ringden O, Pavletic SZ, Anasetti C et al. The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation. Blood 2009; 113: 3110-3118.
27. Marks DI, Perez WS, He W et al. Unrelated donor transplants in adults with Philadelphia-negative acute lymphoblastic leukemia in first complete remission. Blood 2008; 112: 426-434.
28. Gokbuget N, Hoelzer D, Arnold R et al. Treatment of adult ALL according to protocols of the German Multicenter Study Group for Adult ALL (GMALL). Hematol Oncol Clin North Am 2000; 14: 1307-1325.
29. Glucksberg H, Storb R, Fefer A et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974; 18: 295-304.
30. Shulman HM, Sullivan KM, Weiden PL et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204-217.
31. Lutz C, Massenkeil G, Nagy M et al. A pilot study of prophylactic donor lymphocyte infusions to prevent relapse in adult acute lymphoblastic leukemias after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2008; 41: 805-812.
32. Massenkeil G, Nagy M, Lawang M et al. Reduced intensity conditioning and prophylactic DLI can cure patients with high-risk acute leukaemias if complete donor chimerism can be achieved. Bone Marrow Transplant 2003; 31: 339-345.
33. Klein JP, Rizzo JD, Zhang MJ et al. Statistical methods for the analysis and presentation of the results of bone marrow transplants. Part 2: Regression modeling. Bone Marrow Transplant 2001; 28: 1001-1011.
34. Zikos P, Van Lint MT, Lamparelli T et al. Allogeneic hemopoietic stem cell transplantation for patients with high risk acute lymphoblastic leukemia: favorable impact of chronic graft-versus-host disease on survival and relapse. Haematologica 1998; 83: 896-903.
35. Yanada M, Naoe T, Iida H et al. Myeloablative allogeneic hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia in adults: significant roles of total body irradiation and chronic graftversus-host disease. Bone Marrow Transplant 2005; 36: 867-872.
36. Fielding AK, Rowe JM, Richards SM et al. Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International ALL Trial MRC UKALLXII/ECOG2993. Blood 2009; 113: 4489-4496.
37. Cornelissen JJ, Carston M, Kollman C et al. Unrelated marrow transplantation for adult patients with poor-risk acute lymphoblastic leukemia: strong graft-versusleukemia effect and risk factors determining outcome. Blood 2001; 97: 1572-1577.
38. Dahlke J, Kroger N, Zabelina T et al. Comparable results in patients with acute lymphoblastic leukemia after related and unrelated stem cell transplantation. Bone Marrow Transplant 2006; 37: 155-163.
39. Hahn T, McCarthy PL, Jr, Zhang MJ et al. Risk factors for acute graft-versushost disease after human leukocyte antigen-identical sibling transplants for adults with leukemia. J Clin Oncol 2008; 26: 5728-5734.
40. Friedrichs B, Tichelli A, Bacigalupo A et al. Long-term outcome and late effects in patients transplanted with mobilised blood or bone marrow: a randomised trial. Lancet Oncol 2010; 11: 331-338.
41. Pidala J, Tomblyn M, Nishihori T et al. ATG prevents severe acute graft-versushost disease in mismatched unrelated donor hematopoietic cell transplantation. Biol Blood Marrow Transplant 2011; 17: 1237-1244.
42. Finke J, Bethge WA, Schmoor C et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol 2009; 10: 855-864.
43. Theurich S, Fischmann H, Shimabukuro-Vornhagen A et al. Polyclonal antithymocyte globulins for the prophylaxis of graft-versus-host disease after allogeneic stem cell or bone marrow transplantation in adults. Cochrane Database Syst Rev 2012; 9: CD009159.
44. Kiehl MG, Kraut L, Schwerdtfeger R et al. Outcome of allogeneic hematopoietic stem-cell transplantation in adult patients with acute lymphoblastic leukemia: no difference in related compared with unrelated transplant in first complete remission. J Clin Oncol 2004; 22: 2816-2825.
45. Bader P, Kreyenberg H, Hoelle W et al. Increasing mixed chimerism is an important prognostic factor for unfavorable outcome in children with acute lymphoblastic leukemia after allogeneic stem-cell transplantation: possible role for pre-emptive immunotherapy?. J Clin Oncol 2004; 22: 1696-1705.
46. Spyridonidis A, Labopin M, Schmid C et al. Outcomes and prognostic factors of adults with acute lymphoblastic leukemia who relapse after allogeneic hematopoietic cell transplantation. An analysis on behalf of the Acute Leukemia Working Party of EBMT. Leukemia 2012; 26: 1211-1217.
47. Lankester AC, Bierings MB, van Wering ER et al. Preemptive alloimmune intervention in high-risk pediatric acute lymphoblastic leukemia patients guided by minimal residual disease level before stem cell transplantation. Leukemia 2010; 24: 1462-1469.